Vigilant Biosciences, Inc., a Ft. Lauderdale, FL-based developer of solutions that aid in the early detection and intervention of cancer, completed a $5m Series B2 financing.
Backers included White Owl Capital Partners, venVelo and others, as well as a group of private and angel investors with a commitment to the life sciences.
This funding, which brought the Series B round to $10.5m and the total amount of funding raised to date to $12.5m, will allow the company to expand commercial and development efforts the continued research and development of additional products
Led by Matthew H.J. Kim, Founder, Chairman, and CEO, Vigilant Biosciences develops solutions that aid clinicians in the early detection and intervention of cancer.
The Vigilant Biosciences OncAlert™ Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that allow healthcare practitioners to improve potential outcomes through earlier intervention. Its patented technology measures a large combination of soluble CD44, a tumor-initiating and stem cell associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse.
The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S.
The OraMark™ Test is a Laboratory Developed Test (LDT) that is available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies.